Several of the tests are Research Use Only (RUO) such as the RUO LENA Q51® introduced by Alercell in January 2023. LENA Q51® is the most comprehensive test and covers all the other tests but Alercell wanted to give access to all tests thru the creation of the Platform. Alercell R&D team is constantly working to add new tests to cover all the aspects of Leukemia testing to provide practitioners with every single test available in one place.

Alercell is making sure that all the tests are offered at very competitive pricing.  Alercell strong belief is that giving access to many patients, hospitals and cancer centers to quality testing at a limited price will increase the quantity of patients tested, thus will permit early detection and fast treatment of Leukemia. Practitioners should take treatment decisions based on medical data not on costs or insurance consideration.

The tests have an easy-to-use protocol and can be run on standard qPCR equipment and are designed to handle the workflow in a clinical microbiology lab environment. The tests employ industry standard PCR and DNA purification technology.

Frederic Scheer, chairman & CEO of Alercell, stated, "This new platform was designed to create a one-stop-shop for Leukemia, where practitioners do not need to look for many different manufacturers. Our goal at Alercell is to become the reference for Leukemia and offer a complete solution. Our R&D team is working on additional tests to add to the platform in the months and years to come. I believe that several of the tests designed to improve patient outcomes will assist practitioners in selecting the appropriate therapeutics for Leukemia patients. Early detection drastically enhances the survival rates of patients and Alercell is focusing on making sure that we give every patient the best chances of survival.

"Several of the Tests are Research Use only (RUO) but Initial clinical verifications will start soon, we are pleased to introduce the tests for commercial sale for Research Use Only to hospitals and various cancer centers for control purposes and for pharmaceutical surveillance studies."